InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | 2026-05-26 | Francis Knuettel II | CFO, Treas & Secty | Sale | 1,500 | $26.84 | $40K | 11.3K | View ↗ | |
| 2026-04-02 | 2026-04-06 | Malamut Richard | Director | Sale | 590 | $20.92 | $12K | 27.4K | View ↗ | |
| 2026-04-02 | 2026-04-06 | Friedberg Ezra M | Director | Sale | 558 | $20.92 | $12K | 82.0K | View ↗ | |
| 2026-04-02 | 2026-04-06 | Pauls Matthew | Director | Sale | 786 | $20.92 | $16K | 15.2K | View ↗ | |
| 2026-04-02 | 2026-04-06 | Greenleaf Peter | Director | Sale | 797 | $20.92 | $17K | 24.7K | View ↗ |
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| General and administrative expenses | $4.1M+50.1% | $2.7M+149.3% | $1.1M |
| Research and development | $1.2M-54.3% | $2.6M+558.5% | $392K |
| Professional fees | $2.3M+47.8% | $1.5M+86.6% | $828K |
| Total operating expenses | $7.6M+10.3% | $6.9M+196.0% | $2.3M |
| NET LOSS FROM OPERATIONS | -$7.6M-10.3% | -$6.9M-196.0% | -$2.3M |
| Interest expense | -$786K-51.7% | -$519K-269.2% | -$140K |
| Other income | $39K | — | — |
| Gain on default judgement | $363K | — | — |
| Total other (expense) income | -$383K+26.1% | -$519K-269.2% | -$140K |
| Net loss before provision for income taxes | -$8.0M-7.8% | -$7.4M-200.2% | -$2.5M |
| NET LOSS | -$8.0M-7.8% | -$7.4M-200.2% | -$2.5M |
| Net loss per common share - diluted | -$1.43+75.3% | -$5.78 | — |
| Weighted average number of common shares outstanding during the year - diluted | $5.6M+336.7% | $1.3M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Pelthos outlines mid-2027 XEGLYZE launch timing as ZELSUVMI Q1 net product revenue reaches $10.7M
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript